Based on the Amylyx Pharmaceuticals Inc stock forecast from 2 analysts, the average analyst target price for Amylyx Pharmaceuticals Inc is USD 11.67 over the next 12 months. Amylyx Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amylyx Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Amylyx Pharmaceuticals Inc’s stock price was USD 5.24. Amylyx Pharmaceuticals Inc’s stock price has changed by +31.66% over the past week, +38.62% over the past month and +178.72% over the last year.
No recent analyst target price found for Amylyx Pharmaceuticals Inc
No recent average analyst rating found for Amylyx Pharmaceuticals Inc
Company Overview Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Read Less
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, f...Read More
Frequently Asked Questions About Amylyx Pharmaceuticals Inc (AMLX) Stock
Based on ratings from 2 analysts Amylyx Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AMLX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AMLX is USD 11.67 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 11.
AMLX stock's Price/Earning ratio is 2.51.
Our analysis grades AMLX stock's Price / Earning ratio at D. This means that AMLX stock's Price/Earning ratio is above 37% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AMLX may be fairly valued for its sector
The last closing price of AMLX's stock was USD 5.24.
The most recent market capitalization for AMLX is USD 0.31B.
Based on targets from 2 analysts, the average taret price for AMLX is projected at USD 11.67 over the next 12 months.
This means that AMLX's stock price may go up by +122.65% over the next 12 months.
We can't find any ETFs which contains Amylyx Pharmaceuticals Inc's stock.
As per our most recent records Amylyx Pharmaceuticals Inc has 123 Employees.
Amylyx Pharmaceuticals Inc's registered address is 43 Thorndike Street, Cambridge, MA, United States, 02141.
You can get more information about it from Amylyx Pharmaceuticals Inc's website at https://amylyx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Amylyx Pharmaceuticals Inc (AMLX) Stock
Based on ratings from 2 analysts Amylyx Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AMLX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AMLX is USD 11.67 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 11.
AMLX stock's Price/Earning ratio is 2.51.
Our analysis grades AMLX stock's Price / Earning ratio at D. This means that AMLX stock's Price/Earning ratio is above 37% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AMLX may be fairly valued for its sector
The last closing price of AMLX's stock was USD 5.24.
The most recent market capitalization for AMLX is USD 0.31B.
Based on targets from 2 analysts, the average taret price for AMLX is projected at USD 11.67 over the next 12 months.
This means that AMLX's stock price may go up by +122.65% over the next 12 months.
We can't find any ETFs which contains Amylyx Pharmaceuticals Inc's stock.
As per our most recent records Amylyx Pharmaceuticals Inc has 123 Employees.
Amylyx Pharmaceuticals Inc's registered address is 43 Thorndike Street, Cambridge, MA, United States, 02141.
You can get more information about it from Amylyx Pharmaceuticals Inc's website at https://amylyx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMLX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
